To unlock this feature and to subscribe to our weekly evidence emails, please create a FREE orthoEvidence account.


Already Have an Account?

Visit our Evidence-Based Covid-19 Website and Stay Up to Date with the latest Research.
Vol:6 Issue:1 Number:23 ISSN#:2564-2537
Author Verified
ACE Report #9177
Ace Report Cover Metabolic Disorders

Combination therapy improves site-specific BMD vs. teriparatide & denosumab monotherapies

How to Cite

OrthoEvidence. Combination therapy improves site-specific BMD vs. teriparatide & denosumab monotherapies. ACE Report. 2017;6(1):23. Available from:

Study Type:Therapy
OE Level Evidence:2
Journal Level of Evidence:N/A

Response to Therapy With Teriparatide, Denosumab, or Both in Postmenopausal Women in the DATA (Denosumab and Teriparatide Administration) Study Randomized Controlled Trial

J Clin Densitom. 2016 Jul-Sep;19(3):346-51

Contributing Authors:
BZ Leder JN Tsai RM Neer AV Uihlein PM Wallace SA Burnett-Bowie

Did you know you're eligible to earn 0.5 CME credits for reading this report? Click Here


94 postmenopausal osteoporotic women were randomized to receive either 60mg denosumab subcutaneously every 6 months, 20ug teriparatide subcutaneously daily, or a combination treatment of both 60mg denosumab and 20ug teriparatide for a duration of 24 months. The purpose of this study was to compare the individual response rates of the three treatment groups in terms of increases in bone mineral den...

Ace Report Preview Image
CME Image

Continuing Medical Education Credits

You could be earning 0.5 CME credits for each report you read.

For Reprints and Permissions, click here

Please Login or Join to leave comments.